GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (NAS:HARP) » Definitions » Net Margin %

Harpoon Therapeutics (Harpoon Therapeutics) Net Margin % : -40.51% (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Harpoon Therapeutics's Net Income for the three months ended in Sep. 2023 was $-1.80 Mil. Harpoon Therapeutics's Revenue for the three months ended in Sep. 2023 was $4.45 Mil. Therefore, Harpoon Therapeutics's net margin for the quarter that ended in Sep. 2023 was -40.51%.

The historical rank and industry rank for Harpoon Therapeutics's Net Margin % or its related term are showing as below:

HARP' s Net Margin % Range Over the Past 10 Years
Min: -2377.12   Med: -534.79   Max: -81.67
Current: -81.67


HARP's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -160.92 vs HARP: -81.67

Harpoon Therapeutics Net Margin % Historical Data

The historical data trend for Harpoon Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harpoon Therapeutics Net Margin % Chart

Harpoon Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Margin %
Get a 7-Day Free Trial -576.13 -961.95 -286.10 -493.45 -212.22

Harpoon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.48 -450.45 -132.10 5.25 -40.51

Competitive Comparison of Harpoon Therapeutics's Net Margin %

For the Biotechnology subindustry, Harpoon Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harpoon Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harpoon Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Harpoon Therapeutics's Net Margin % falls into.



Harpoon Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Harpoon Therapeutics's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-67.731/31.915
=-212.22 %

Harpoon Therapeutics's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin=Net Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-1.802/4.448
=-40.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harpoon Therapeutics  (NAS:HARP) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Harpoon Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Harpoon Therapeutics (Harpoon Therapeutics) Business Description

Traded in Other Exchanges
Address
131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Executives
Vijay K Lathi 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK CA 94025
Luke Nathaniel Walker officer: Chief Medical Officer C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Frank J Lanza officer: Principal Fin. & Acctng Ofc. C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lauren P Silvernail director 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Georgia Erbez officer: Chief Financial Officer 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Oncology Impact Fund (cayman) Management L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Alan Colowick director C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
New Leaf Bpo Associates Ii, L.p. 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
Ronald Hunt director, 10 percent owner C/O CREDIT SUISSE 1ST BOSTON PRV EQY, 11 MADISON AVENUE, NEW YORK NY 10010
New Leaf Bpo Management Ii, L.l.c 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
New Leaf Ventures Iii, L.p. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Associates Iii, L.p. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Management Iii, L.l.c. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Biopharma Opportunities Ii, L.p. 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170